Driving Precision Medicine in CNS Disorders

Neurodegenerative and neuropsychiatric diseases represent one of the largest areas of unmet medical need to healthcare systems in the world today.

Disorders of the central nervous system are a major focus for PrecisionLife.  We’ve completed analyses in more than a dozen indications and continue to add to the list as datasets become available.

Our AI-led combinatorial analysis approach is particularly well-suited to these complex, heterogeneous diseases and we have successfully revealed subgroups within the patient populations that point to previously unknown underlying pathologies, some of which are common across the indications, enabling targeted precision medicine R&D programs in CNS disorders.

Our on-going work includes:

1. Actively working with our partners to validate entirely novel therapeutic targets in both ALS and schizophrenia
2. Using our patient stratification biomarkers to explore mechanisms of action and more targeted use of existing therapies to treat disease
3. Identifying novel causal biology and genetic risk factors
4. Completing analyses of a new dataset from Alzheimer’s disease to support findings from our previous studies

View recent research articles, videos and news, about our precision neuroscience and CNS programs below.

Recent Posters
Identifying actively protective biology, novel causal targets,  and mechanistic patient stratification biomarkers in ALS	Identifying actively protective biology, novel targets  & mechanistic biomarkers in Alzheimer's disease

Precision Medicine for Amyotrophic Lateral Sclerosis: Combinatorial Analysis of Patient Genomes	Precision Medicine for Alzheimer’s Disease: Identifying Effective Therapeutic Strategies with Stratification Biomarkers

Cross-disorder Patient and Mechanistic Stratification using Combinatorial Analyses	Cross-Disease Mechanisms Identified in ALS and FTD Patient Genomes

Disease Studies
Multiple patient subgroups discovered with distinct mechanistic etiologies, novel targets and biomarkers		Identifying novel targets with genetic linkage to stratified patient subgroups

Mechanism-based patient stratification enables novel target discovery and repurposing opportunities

Articles

 

A New Era of Precision Neuroscience Drug Discovery World  |  Guide to Neuroscience R&D	Unlocking R&D Innovation for CNS Diseases Precision Medicine Quarterly  |  Volume 1

 

 

Related News

Ono Pharmaceutical Enters into a Multi Target CNS R&D Collaboration with PrecisionLife Nxera Pharma and PrecisionLife Expand Strategic Neuroscience R&D Partnership PrecisionLife and NATA Announce R&D Partnership to Jointly Develop New MND/ALS Drug Programme Agreement with King’s College London to Enable New Precision Neuroscience Treatments in MND/ALS

 

About PrecisionLife

PrecisionLife is a pioneering precision medicine company changing the way the world predicts, prevents, and treats complex, chronic diseases by finding better, more personalized diagnostic and treatment options for patients.

Our platform is unique in its ability to identify causal biology and link chronic disease patients to effective treatments via the molecular mechanism of their disease or drug response. These insights enable us to significantly improve probabilities of success across the biopharma and healthcare value chain.

Contact us via the form below to find out more.